| Ipilimumab |
CTLA-4 Antibody |
Melanoma metastatic |
2011 |
| Nivolumab |
Check-point inhibitor |
Non-small cell lung cancer metastatic progressive |
2015 |
|
|
Melanoma unresectable or metastatic |
2015 |
|
|
Renal cell cancer advanced previously treated |
2015 |
|
|
Small cell lung cancer, metastatic |
2016 |
|
|
Small cell lung cancer, metastatic in combination with ipilimumab |
2016 |
|
|
Head and neck cancer, squamous cell, recurrent or metastatic |
2016 |
|
|
Urothelial carcinoma, locally advanced or metastatic |
2017 |
|
|
Melanoma unresectable previously untreated, with ipilimumab combination |
2017 |
|
|
Melanoma metastatic with brain metastasis |
2018 |
|
|
Renal cell cancer advanced previously untreated with ipilimumab combination |
2018 |
| Pembrolizumab |
Anti PD1 monoclonal antibody |
Melanoma unresectable or metastatic |
2015 |
|
|
Merkel cell carcinoma, recurrent or metastatic |
2016 |
|
|
Non-small cell lung cancer, metastatic, single agent |
2016 |
|
|
Primary mediastinal large B cell, relapsed or refractory |
2017 |
|
|
Urothelial carcinoma, locally advanced or metastatic |
2017 |
|
|
Non-small cell lung cancer, non-squamous, metastatic in combination |
2018 |
|
|
Non-small cell lung cancer, squamous, metastatic in combinations |
2018 |
|
|
Melanoma Stage III adjuvant |
2018 |
|
|
Cervical cancer recurrent or metastatic |
2018 |
|
|
Gastric cancer recurrent locally advanced or metastatic |
2018 |
|
|
Hepatocellular carcinoma advanced |
2018 |
|
|
Head and neck cancer, squamous cell, recurrent or metastatic |
2018 |
| Ibrutinib |
Bruton tyrosine kinase inhibitor |
Mantle cell lymphoma |
2013 |
|
|
CLL/SLL monotherapy or in combination BR or obinutuzumab |
2014 |
|
|
CLL/SLL with 17p deletion |
2014 |
|
|
Waldenstrom macroglobulinemia, monotherapy or rituximab combination |
2015 |
|
|
Marginal zone lymphoma |
2017 |
| Axicabtagene ciloleucel |
CAR T-cell immunotherapy |
Large B cell lymphoma |
2017 |
| Tisagenlecleucel |
CAR T-cell immunotherapy |
Acute lymphoblastic lymphoma-relapsed or refractory |
2017 |
|
|
Diffuse large B cell relapsed or refractory |
2017 |
